Drug Profile
MTC 896
Alternative Names: MTC896Latest Information Update: 21 Sep 2020
Price :
$50
*
At a glance
- Originator Mimetica
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Melanocortin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 21 Sep 2020 No development reported - Phase-II for Acne vulgaris (In volunteers) in Australia (Topical)
- 21 Sep 2020 No development reported - Phase-II for Acne vulgaris in USA (Topical)
- 05 Dec 2017 Phase-II development for Acne vulgaris is ongoing in USA and Australia (Topical) (Mimetica website, December 2017)